Renaissance Capital logo

Akcea Therapeutics Priced, Nasdaq: AKCA

Late-stage biotech developing therapies for rare lipid disorders.

Industry: Health Care

First Day Return: +18.5%

Industry: Health Care

We are a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Our goal is to become the premier company offering treatments for inadequately treated lipid disorders. We are advancing a mature pipeline of four novel drugs with the potential to treat multiple diseases. Our drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals (Nasdaq: IONS). Our most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy (FPL). FCS and FPL are both severe, rare, genetically defined lipid disorders characterized by extremely elevated levels of triglycerides. Both diseases have life-threatening consequences and the lives of patients with these diseases are impacted daily by the associated symptoms. In our clinical program, we have observed consistent and substantial (>70%) decreases in triglycerides and improvements in other manifestations of FCS, including pancreatitis attacks and abdominal pain. We believe the safety and efficacy data from the volanesorsen program demonstrate a favorable risk-benefit profile for patients with FCS. In the thrid quarter of 2017, we plan to file for marketing authorization for volanesorsen to treat patients with FCS.
more less
IPO Data
IPO File Date 03/27/2017
Offer Price $8.00
Price Range $12.00 - $14.00
Offer Shares (mm) 15.6
Deal Size ($mm) $125
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/13/2017
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $125
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Cambridge, MA, United States
Founded 2015
Employees at IPO 30
Website www.akceatx.com

Akcea Therapeutics (AKCA) Performance